302 related articles for article (PubMed ID: 16533786)
1. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.
Pieretti-Vanmarcke R; Donahoe PK; Szotek P; Manganaro T; Lorenzen MK; Lorenzen J; Connolly DC; Halpern EF; MacLaughlin DT
Clin Cancer Res; 2006 Mar; 12(5):1593-8. PubMed ID: 16533786
[TBL] [Abstract][Full Text] [Related]
2. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
3. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
4. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Pieretti-Vanmarcke R; Donahoe PK; Pearsall LA; Dinulescu DM; Connolly DC; Halpern EF; Seiden MV; MacLaughlin DT
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17426-31. PubMed ID: 17088539
[TBL] [Abstract][Full Text] [Related]
5. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
6. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
[TBL] [Abstract][Full Text] [Related]
7. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
8. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
[TBL] [Abstract][Full Text] [Related]
9. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
[TBL] [Abstract][Full Text] [Related]
10. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology of MIS and its receptors.
Teixeira J; Donahoe PK
J Androl; 1996; 17(4):336-41. PubMed ID: 8889695
[TBL] [Abstract][Full Text] [Related]
12. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
[TBL] [Abstract][Full Text] [Related]
14. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
15. The müllerian inhibitor and mammalian sexual development.
Behringer RR
Philos Trans R Soc Lond B Biol Sci; 1995 Nov; 350(1333):285-8; discussion 289. PubMed ID: 8570693
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium.
Wang J; Dicken C; Lustbader JW; Tortoriello DV
Fertil Steril; 2009 Apr; 91(4):1195-203. PubMed ID: 18328480
[TBL] [Abstract][Full Text] [Related]
17. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
[TBL] [Abstract][Full Text] [Related]
18. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
[TBL] [Abstract][Full Text] [Related]
19. Abnormal sexual development in transgenic mice chronically expressing müllerian inhibiting substance.
Behringer RR; Cate RL; Froelick GJ; Palmiter RD; Brinster RL
Nature; 1990 May; 345(6271):167-70. PubMed ID: 2336108
[TBL] [Abstract][Full Text] [Related]
20. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
